In a separate clinical trial (NCT03166878), the allogeneic universal CD19-specific CAR-T cells (UCART019) from gene-edited patients with relapsed or refractory CD19+ lymphoma and leukemia were given to patients using LV as a delivery vehicle at the dosage of 5E6 CAR-T cells/kg enveloped by LV. Here, CD19 is linked to lymphoma.